cas2412-sup-0001-FigureS1.tifimage/tif4304KFig. S1. Characterization of 786-O subclones with different status of VHL and hypoxia-inducible factor (HIF) reactivity.
cas2412-sup-0002-FigureS2.tifimage/tif4304KFig. S2. Xenograft formation of 786-O subclones.
cas2412-sup-0003-FigureS3.tifimage/tif4304KFig. S3. Effect of bevacizumab treatment on the cell proliferation of 786-O subclones in vitro.
cas2412-sup-0004-FigureS4.tifimage/tif4303KFig. S4. Quantitative PCR analysis of several angiogenesis-related genes in 786-O subclones with different statuses of VHL and hypoxia-inducible factor (HIF) reactivity.
cas2412-sup-0005-FigureS5.tifimage/tif4304KFig. S5. Oncomine database analysis of a series of angiogenesis-related genes regulated by VHL in normal kidney versus clear cell renal cell carcinomas.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.